Movatterモバイル変換


[0]ホーム

URL:


CN101696959B - A kind of method for the content determination of atosiban acetate and its preparation and the determination of related substances - Google Patents

A kind of method for the content determination of atosiban acetate and its preparation and the determination of related substances
Download PDF

Info

Publication number
CN101696959B
CN101696959BCN200910008881ACN200910008881ACN101696959BCN 101696959 BCN101696959 BCN 101696959BCN 200910008881 ACN200910008881 ACN 200910008881ACN 200910008881 ACN200910008881 ACN 200910008881ACN 101696959 BCN101696959 BCN 101696959B
Authority
CN
China
Prior art keywords
solution
mobile phase
atosiban
sample
peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200910008881A
Other languages
Chinese (zh)
Other versions
CN101696959A (en
Inventor
崔学云
周宗贞
杨平
马中刚
王文
付建兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Zhonghe Pharmaceutical Co ltd
Original Assignee
HAINAN ZHONGHE POLYPEPTIDE RESEARCH Co Ltd
HAINAN ZHONGHE PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAINAN ZHONGHE POLYPEPTIDE RESEARCH Co Ltd, HAINAN ZHONGHE PHARMACEUTICAL CO LtdfiledCriticalHAINAN ZHONGHE POLYPEPTIDE RESEARCH Co Ltd
Priority to CN200910008881ApriorityCriticalpatent/CN101696959B/en
Publication of CN101696959ApublicationCriticalpatent/CN101696959A/en
Application grantedgrantedCritical
Publication of CN101696959BpublicationCriticalpatent/CN101696959B/en
Expired - Fee Relatedlegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Images

Landscapes

Abstract

The invention relates to an acetic acid atosiban, and a method for detecting content of preparation of acetic acid atosiban and relevant substances. The detection method is an efficient liquid-phase chromatography method, which comprises the following chromatography conditions that a chromatographic column takes octadecylsilane chemically bonded silica (C18) as filling agent; 0.05mol/L phosphate buffer solution is taken as mobile phase A and acetonitrile as mobile phase B to carry out gradient elution; a detection wavelength ranges from 205 to 225nm; the flow speed ranges between 0.8 and 1.2ml/min and the concentration of a prepared sample ensures that each milliliter of the sample contains 0.1 to 15mg of polypeptide; and the sample size is controlled between 5 and 200mu l. The efficient liquid-phase chromatography method can accurately detect a sample and the content of impurities of the sample at the same time and realizes complete sample separation during analysis and ideal reproducibility of analysis result, thereby providing a simple and reliable method for quality control and analysis during production process.

Description

The assay of a kind of acetic acid Atosiban and preparation thereof and the method for determination of related substances
Technical field:
The present invention relates to the method detection method of a kind of active peptides raw material medicine and preparation, especially relate to the assay of acetic acid Atosiban and preparation thereof and the method for determination of related substances.
Background technology:
Atosiban (atosiban), its chemical name is: 1-(3-mercaptan lactic acid)-2-(O-ethyl-D tyrosine)-4-L-threonine-8-L-ornithine-oxytocins.
Its structural formula is:
Figure G2009100088810D00011
Atosiban is a kind of oxytocins analog, is the ring type polypeptide of synthetic, is the oxytocins competitive antagonist of acceptor on intrauterine and decidua, the fetal membrane, uses its acetate treatment premature labor clinically.Acetic acid Atosiban parenteral solution (AtosibanAcetate Injection) is developed by Huiling Co.,Ltd (Ferring AB); On March 23rd, 2000, in Austria's listing, commodity were by name: first
The related substance and the content detecting method of acetic acid Atosiban and acetic acid Atosiban parenteral solution are not appeared in the newspapers as yet; The difficulty of its assay method is in its building-up process, may produce disappearance (not exclusively) peptide, the peptide that ruptures, removes kinds of processes impurity such as acid amides polypeptide, diastereoisomeric polypeptide and oligomer; After carrying out purifying through chromatography; The impurity that can't remove is more similar with the chromatographic behavior of main ingredient, is difficult for separating fully.
Summary of the invention:
The purpose of this invention is to provide and a kind ofly can measure acetic acid Atosiban [1-(3-mercaptan lactic acid)-2-(O-ethyl-D tyrosine)-4-threonine-8-ornithine-oxytocins acetate] and the content of acetic acid Atosiban preparation and the detection method of related substance.
Acetic acid Atosiban content assaying method of the present invention is following:
Adopt reversed-phased high performace liquid chromatographic to detect the content of acetic acid Atosiban in 1-(3-mercaptan lactic acid)-2-(O-ethyl-D tyrosine)-4-threonine-8-ornithine-oxytocins acetate and the preparation thereof, its step comprises:
1) sample thief is an amount of, is mixed with the solution that contains 0.75mg among every 1ml with mobile phase A, as need testing solution;
2) it is an amount of to take by weighing reference substance in addition, processes the solution that contains 0.75mg among every 1ml with mobile phase A dissolving and dilution, as reference substance solution;
3) measure each 20 μ l of need testing solution and reference substance solution, inject liquid chromatograph respectively, the record chromatogram with calculated by peak area, obtains the content of acetic acid Atosiban in the sample by external standard method.
Chromatographic condition:
Use octadecylsilane chemically bonded silica to be filling agent; Phosphate buffer (get potassium dihydrogen phosphate 6.8g, add water to 1000ml, with phosphorus acid for adjusting pH value to 2.3, add 120 μ l triethylamines again, promptly get) with 0.05mol/L is a mobile phase A, and acetonitrile is a Mobile phase B, carries out gradient elution; The detection wavelength is 215nm; Flow velocity is 1.0ml/min.Theoretical cam curve is calculated by the Atosiban peak should be not less than 5000.The gradient elution program is following:
Figure G2009100088810D00021
Wherein reference substance is the pure article of acetic acid Atosiban, can buy from the reagent shop.
Its related substances assay method of the present invention, step is following:
1) sample thief is an amount of, adds moving phase and is mixed with the solution that contains 1.5mg among every 1ml approximately, as need testing solution;
2) measure need testing solution 1ml, put in the 100ml measuring bottle, add mobile phase A and be diluted to scale, shake up, as contrast solution;
3) get contrast solution 20 μ l and inject liquid chromatograph; Regulate detection sensitivity; Make major component chromatographic peak peak height be about 20% of full scale, precision is measured need testing solution and each 20 μ l of contrast solution again, injects liquid chromatograph respectively; 2 times of record chromatogram to major component peak retention time calculate its related substances.
Chromatographic condition:
Use octadecylsilane chemically bonded silica to be filling agent; Phosphate buffer (get potassium dihydrogen phosphate 6.8g, add water 1000ml, with phosphorus acid for adjusting pH value to 2.3, add 120 μ l triethylamines again, promptly get) with 0.05mol/L is a mobile phase A, and acetonitrile is a Mobile phase B, carries out gradient elution; The detection wavelength is 220nm; Flow velocity is 1.0ml/min.Theoretical cam curve is calculated by the Atosiban peak should be not less than 5000.The gradient elution program is following:
Figure G2009100088810D00022
Figure G2009100088810D00031
Wherein said related substance is meant the impurity component that has in the acetic acid Atosiban building-up process, like solvent, and intermedium, raw material, amino acid fragments etc., impurity component are measured the related substance purpose and are to limit its content for being constrained to branch.
The characteristics of assay method of the present invention are: separate between each composition in the analyte thoroughly, workable, the analytical approach specificity is strong, accuracy and highly sensitive, adaptability is by force for guaranteeing drug safety, effective, the controlled foundation that provides.
Description of drawings:
Fig. 1 is 0.1% trifluoroacetic acid: acetonitrile is the chromatogram of moving phase
Fig. 2 is the 0.05mol/L phosphate buffer: acetonitrile is the chromatogram of moving phase
Fig. 3 is specificity experiment chromatogram.
Fig. 4 is the detectability chromatogram.
Fig. 5 is the chromatogram of sample determination of related substances.
The chromatogram that Fig. 6 measures for sample size.
Embodiment:
Following examples are used to explain the present invention, but not as limitation of the present invention.
Embodiment 1
Acetic acid Atosiban content assaying method
Experimental apparatus and chromatographic condition:
Waters 515-717-2996 high performance liquid chromatograph, Agilent C18 chromatographic column (5 μ m, 150 * 4.6mm); Phosphate buffer with 0.05mol/L (is got potassium dihydrogen phosphate 6.8g, is added water 1000ml, with phosphorus acid for adjusting pH value to 2.0~3.0; Add 120 μ l triethylamines again, promptly get) be mobile phase A, acetonitrile is a Mobile phase B; Carry out gradient elution, the detection wavelength is 205~225nm; Flow velocity is 0.8~1.2ml/min; Sample size is 5~200 μ l.。
Reagent:
Acetonitrile (HPLC level) is from U.S. world company, and ultrapure water is the self-control of Millipore ultrapure water machine.
The selection of chromatographic condition
1.1 moving phase
We have compared 0.1% trifluoroacetic acid (TFA) through experiment: acetonitrile (ACN) and 0.05mol/L phosphate buffer (PBS): ACN, and as moving phase, baseline fluctuation is big with 0.1% trifluoroacetic acid aqueous solution, and impurity peaks can't separate interference measurement fully with main peak; And be moving phase with 0.05mol/L, baseline is steady, and impurity peaks can separate with main peak fully, and the symmetry of main peak good (seeing Fig. 1 and Fig. 2).
1.2 detection wavelength
Carry out continuous sweep with ultraviolet spectrophotometer at 200~400nm, sample has absorption maximum at the 215nm place, and related substance has stronger absorption at the 220nm place mostly.Consider the baseline noise simultaneously to interference that detects and the sensitivity that takes into account mensuration, the detection wavelength of selection determination of related substances is decided to be 220nm, and the detection wavelength of assay is 215nm.
1.3 sample concentration
The concentration of these article preparation is 7.5mg/ml; Accurate for convenient experimental operation, having compared concentration respectively is the chromatogram of 0.75mg/ml and 1.5mg/ml test sample, and experimental result shows; Concentration is that the peak height and the area of sample impurity peaks of 1.5mg/ml is all more remarkable; And do not cause the chromatographic column overload, the concentration that therefore defines the related substance working sample is 1.5mg/ml, and the concentration of assay sample is 0.75mg/ml.
The checking of testing conditions
2.1 specificity
Sample thief is an amount of, adds mobile phase A dissolving and dilution and processes the solution that concentration is 1.5mg/ml, and every 1ml adds about 5 of 10% sodium hydroxide solution, and room temperature was placed 25 minutes, got 20 μ l injecting chromatographs, record chromatogram (see figure 3).The result shows that under the testing conditions, other components and main peak all can reach baseline separation in the sample after the destruction once more, and specificity is strong.
2.2 detectability
Sample thief is an amount of, add mobile phase A dissolving and dilution after, get 20 μ l and inject liquid chromatograph, the record chromatogram is three times of baseline noise until the main peak peak height, records limit of identification and is about 33.4ng.
2.3 the recovery
Sample thief is an amount of, is mixed with 0.6mg/ml, a 0.75mg/ml and 0.9mg/ml3 concentration respectively, and each 3 increment of each concentration are got 20 μ l injecting chromatographs, calculate recovery rate.The average recovery rate of this method is 100.0%, and RSD% is 0.1%.
Sample determination
3.1 related substance
These article of getting are an amount of, add moving phase and are mixed with the solution that contains 1.5mg among every 1ml approximately, as need testing solution; Precision is measured need testing solution 1ml, puts in the 100ml measuring bottle, adds mobile phase A and is diluted to scale, shakes up, as contrast solution.Get contrast solution 20 μ l and inject liquid chromatograph; Regulate detection sensitivity, make major component chromatographic peak peak height be about 20% of full scale, precision is measured need testing solution and each 20 μ l of contrast solution again; Inject liquid chromatograph respectively, 2 times of (see figure 5)s of record chromatogram to major component peak retention time.
3.2 assay
These article of getting are an amount of, are mixed with the solution that contains 0.75mg among every 1ml with mobile phase A, as need testing solution; It is an amount of that precision takes by weighing reference substance in addition, processes the solution that contains 0.75mg among every 1ml with mobile phase A dissolving and dilution, as reference substance solution.Precision is measured need testing solution and each 20 μ l of reference substance solution, injects liquid chromatograph respectively, and the record chromatogram with calculated by peak area, promptly gets (see figure 6) by external standard method.

Claims (2)

Translated fromChinese
1.一种醋酸阿托西班含量测定方法,其特征是,其步骤包括:1. a method for assaying atosiban acetate content, is characterized in that, its step comprises:1)取醋酸阿托西班原料或制剂样品适量,用流动相A配制成每1ml中含0.75mg的溶液,作为供试品溶液;1) get an appropriate amount of atosiban acetate raw material or preparation sample, be mixed with the solution that contains 0.75mg in every 1ml with mobile phase A, as need testing solution;2)另精密称取对照品适量,用流动相A溶解并稀释制成每1ml中含0.75mg的溶液,作为对照品溶液;2) In addition, accurately weigh an appropriate amount of the reference substance, dissolve and dilute it with mobile phase A to make a solution containing 0.75 mg per 1 ml, as the reference substance solution;3)精密量取供试品溶液与对照品溶液各20μl,分别注入液相色谱仪,记录色谱图,按外标法以峰面积计算,得到样品中醋酸阿托西班的含量;3) Precisely measure 20 μ l of the test solution and the reference solution, inject them into the liquid chromatograph respectively, record the chromatogram, calculate the peak area by the external standard method, and obtain the content of atosiban acetate in the sample;色谱条件为:The chromatographic conditions are:色谱柱:以十八烷基硅烷键合硅胶C18为填充剂,Chromatographic column: Octadecylsilane bonded silica gel C18 as filler,流动相:以0.05mol/L的磷酸盐缓冲液为流动相A,乙腈为流动相B,Mobile phase: 0.05mol/L phosphate buffer as mobile phase A, acetonitrile as mobile phase B,洗脱方式:梯度洗脱,Elution method: gradient elution,流速:1.0ml/min,Flow rate: 1.0ml/min,检测波长:UV 215nm,Detection wavelength: UV 215nm,其中,对照品为醋酸阿托西班纯品,Wherein, the reference substance is atosiban acetate pure product,含量测定的方法为:照中国药典2005年版二部附录V D高效液相色谱法测定;The method for content determination is: measure according to two appendices V D high performance liquid chromatography of Chinese Pharmacopoeia edition in 2005;色谱条件与系统适用性试验理论塔板数按阿托西班峰计算应不低于5000,梯度洗脱程序如下:Chromatographic conditions and system suitability test The theoretical plate number should not be less than 5000 based on the calculation of the atosiban peak, and the gradient elution procedure is as follows:
Figure FSB00000875893400011
Figure FSB00000875893400011
其中,磷酸盐缓冲液的配制方法为:取磷酸二氢钾6.8g,加水1000ml,用磷酸调节pH值至2.3,再加入120μl三乙胺,即得。Among them, the preparation method of the phosphate buffer solution is as follows: take 6.8 g of potassium dihydrogen phosphate, add 1000 ml of water, adjust the pH value to 2.3 with phosphoric acid, and then add 120 μl of triethylamine to obtain the product.2.一种醋酸阿托西班有关物质的检测方法,其特征在于:2. a detection method for atosiban acetate related substances, characterized in that:1)取醋酸阿托西班原料或制剂样品适量,加流动相配制成每1ml中约含1.5mg的溶液,作为供试品溶液;1) Get an appropriate amount of atosiban acetate raw material or preparation sample, add mobile phase and be mixed with the solution that contains about 1.5mg in every 1ml, as need testing solution;2)精密量取供试品溶液1ml,置100ml量瓶中,加流动相A稀释至刻度,摇匀,作为对照溶液;2) Precisely measure 1ml of the test solution, put it in a 100ml measuring bottle, add mobile phase A to dilute to the mark, shake well, and use it as a control solution;3)取对照溶液20μl注入液相色谱仪,调节检测灵敏度,使主成分色谱峰峰高约为满量程的20%,再精密量取供试品溶液和对照溶液各20μl,分别注入液相色谱仪,记录色谱图至主成分峰保留时间的2倍,计算有关物质含量;3) Take 20 μl of the control solution and inject it into the liquid chromatograph, adjust the detection sensitivity so that the peak height of the main component chromatographic peak is about 20% of the full scale, then accurately measure 20 μl each of the test solution and the control solution, and inject them into the liquid chromatograph respectively instrument, record the chromatogram to twice the retention time of the main component peak, and calculate the content of related substances;色谱条件为:The chromatographic conditions are:色谱柱:以十八烷基硅烷键合硅胶C18为填充剂,Chromatographic column: Octadecylsilane bonded silica gel C18 as filler,流动相:以0.05mol/L的磷酸盐缓冲液为流动相A,乙腈为流动相B,Mobile phase: 0.05mol/L phosphate buffer as mobile phase A, acetonitrile as mobile phase B,洗脱方式:梯度洗脱,Elution method: gradient elution,流速:1.0ml/min,Flow rate: 1.0ml/min,检测波长:UV220nm,Detection wavelength: UV220nm,有关物质检测的的方法为:照中国药典2005年版二部附录V D高效液相色谱法测定The method for the detection of related substances is: according to the Chinese Pharmacopoeia 2005 edition two appendix V D high performance liquid chromatography determination色谱条件与系统适用性试验理论塔板数按阿托西班峰计算应不低于5000,梯度洗脱程序如下:Chromatographic conditions and system suitability test The theoretical plate number should not be less than 5000 based on the calculation of the atosiban peak, and the gradient elution procedure is as follows:
Figure FSB00000875893400021
Figure FSB00000875893400021
其中,磷酸盐缓冲液的配制方法为:取磷酸二氢钾6.8g,加水1000ml,用磷酸调节pH值至2.3,再加入120μl三乙胺,即得。Among them, the preparation method of the phosphate buffer solution is as follows: take 6.8 g of potassium dihydrogen phosphate, add 1000 ml of water, adjust the pH value to 2.3 with phosphoric acid, and then add 120 μl of triethylamine to obtain the product.
CN200910008881A2009-02-112009-02-11 A kind of method for the content determination of atosiban acetate and its preparation and the determination of related substancesExpired - Fee RelatedCN101696959B (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN200910008881ACN101696959B (en)2009-02-112009-02-11 A kind of method for the content determination of atosiban acetate and its preparation and the determination of related substances

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN200910008881ACN101696959B (en)2009-02-112009-02-11 A kind of method for the content determination of atosiban acetate and its preparation and the determination of related substances

Publications (2)

Publication NumberPublication Date
CN101696959A CN101696959A (en)2010-04-21
CN101696959Btrue CN101696959B (en)2012-10-17

Family

ID=42142074

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN200910008881AExpired - Fee RelatedCN101696959B (en)2009-02-112009-02-11 A kind of method for the content determination of atosiban acetate and its preparation and the determination of related substances

Country Status (1)

CountryLink
CN (1)CN101696959B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN103421092B (en)*2013-09-052015-05-13杭州阿德莱诺泰制药技术有限公司Atosiban purification method
CN105503828A (en)*2015-12-242016-04-20北京康立生医药技术开发有限公司Preparation method of fumarate of pyrrole derivatives
CN106018584A (en)*2016-05-122016-10-12华润双鹤利民药业(济南)有限公司Detection method for dezocine related substances
CN106932347B (en)*2017-05-172019-04-12浙江遂昌利民科技有限公司A kind of mezlocillin and its quality index detection method
CN107312072A (en)*2017-06-202017-11-03浙江湃肽生物有限公司A kind of method of purifies and separates Atosiban
CN109142580A (en)*2018-09-122019-01-04南京康舟医药科技有限公司Measure method of the atosiban acetate in relation to substance
CN110218242A (en)*2019-06-262019-09-10海南中和药业股份有限公司A kind of preparation method of atosiban acetate impurity
CN110658297B (en)*2019-10-302021-12-10海南通用三洋药业有限公司Method for detecting high-molecular polymer in terlipressin for injection
CN110658296A (en)*2019-10-302020-01-07海南通用三洋药业有限公司Method for detecting high-molecular polymer in atosiban acetate injection
CN118961954A (en)*2024-10-182024-11-15南京恒远科技开发有限公司 HPLC Content Determination Method of NH-bis(PEG4-t-butyl ester)

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN101314613A (en)*2008-05-082008-12-03吉尔生化(上海)有限公司Solid phase synthesis method for atosiban
CN101357937A (en)*2007-07-312009-02-04崔颀Method for synthesizing atosiban acetate from solid phase polypeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN101357937A (en)*2007-07-312009-02-04崔颀Method for synthesizing atosiban acetate from solid phase polypeptide
CN101314613A (en)*2008-05-082008-12-03吉尔生化(上海)有限公司Solid phase synthesis method for atosiban

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Alan R. Oyler,et al.Hydrophilic interaction chromatography on amino-silica phases complements reversed-phase high-performance liquid chromatography and capillary electrophoresis for peptide analysis.《Journal of Chromatography A》.1996,第724卷第378-383页.*
李萍等.纳升电喷雾串联质谱在阿托西班一级结构确证中的应用.《分析测试学报》.2008,第27卷第16-18页.*

Also Published As

Publication numberPublication date
CN101696959A (en)2010-04-21

Similar Documents

PublicationPublication DateTitle
CN101696959B (en) A kind of method for the content determination of atosiban acetate and its preparation and the determination of related substances
Kang et al.Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring
CN104914185B (en)A kind of Favipiravir has the HPLC assay method of related substance
CN108828127A (en)Liquid-phase chromatography method in relation to substance in a kind of detection Parecoxib Sodium and synthetic intermediate
CN104237421A (en)Related substance detection method for trelagliptin succinate and preparation thereof
CN110146621B (en)Method for determining content of polymer in cephalosporin antibiotic medicine
CN101502616B (en)Method for measuring content of Bletilla striata medicinal materials
CN103698424B (en)Detecting method of detecting organic solvent in slightly-soluble aluminum salt drug
CN107515255A (en)Utilize high performance liquid chromatograph measure Dapagliflozin and its method about material
CN105842365B (en)Utilize the method for efficient liquid phase chromatographic analysis Tadalafei
CN103926335B (en)The high-efficient liquid phase chromatogram process measuring method of related substance in a kind of Dapoxetine hydrochloride
CN1790013B (en) A method for simultaneous determination of protocatechuic acid and 5-hydroxymethylfurfural in Shengmai injection
CN101661019B (en)Method for separating and measuring Palonosetron hydrochloride and optical isomers thereof
CN103163228A (en)Efficient liquid phase analysis method for hydroxyfasudil and preparation thereof
AgrawalValidated stability indicating method for determination of indapamide in pharmaceutical formulation
CN102109501B (en)Method for detecting related substances in quinapril hydrochloride and hydrochlorothiazide composition
CN102579961B (en)Detection method for aristolochic acid A in swelling-reducing and pain-alleviating tincture
CN104965031B (en)Content measuring method for compound ketoprofen and omeprazole sustained-release capsules
CN114518413B (en) A method for determining the content of proline in captopril bulk drug
CN104007185A (en)HPLC determination method for detecting impurities in zanamivir and zanamivir-containing preparation
CN1786706B (en)Cyclovirobuxine D raw medicine and method for determining its content in preparation by chromatography
CN102109499A (en)Method for simultaneously detecting acetone and ethyl acetate residues in drug by gas chromatography
CN106153756A (en)A kind of detect the high performance liquid chromatography of rapamycin in everolimus
Elgawish et al.Quantitative determination of captopril, perindopril erbumine, moexipril hydrochloride, and ramipril in bulk and pharmaceutical preparations by high performance liquid chromatography
CN104165957B (en)The assay method of dimer impurity content in a kind of faropenem sodium raw materials

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
C10Entry into substantive examination
SE01Entry into force of request for substantive examination
C14Grant of patent or utility model
GR01Patent grant
CP03Change of name, title or address

Address after:570216 Haikou Free Trade Zone, Nanhai Road, Hainan, Haikou, China, 168

Co-patentee after:Hainan Zhonghe Polypeptide Research Co.,Ltd.

Patentee after:HAINAN ZHONGHE PHARMACEUTICAL Co.,Ltd.

Address before:570216 Hainan Zhonghe Pharmaceutical Co., Ltd., Haikou, Nanhai Road, No. 168, Hainan, China

Co-patentee before:Hainan Zhonghe Polypeptide Research Co.,Ltd.

Patentee before:HAINAN ZHONGHE PHARMACEUTICAL Co.,Ltd.

CP03Change of name, title or address
TR01Transfer of patent right

Effective date of registration:20170425

Address after:570216 Haikou Free Trade Zone, Nanhai Road, Hainan, Haikou, China, 168

Patentee after:HAINAN ZHONGHE PHARMACEUTICAL Co.,Ltd.

Address before:570216 Haikou Free Trade Zone, Nanhai Road, Hainan, Haikou, China, 168

Co-patentee before:Hainan Zhonghe Polypeptide Research Co.,Ltd.

Patentee before:HAINAN ZHONGHE PHARMACEUTICAL Co.,Ltd.

TR01Transfer of patent right
CF01Termination of patent right due to non-payment of annual fee

Granted publication date:20121017

CF01Termination of patent right due to non-payment of annual fee

[8]ページ先頭

©2009-2025 Movatter.jp